Physician profile
Daniel Asihene
NPI 1639558901
$2,103.29
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $690 · 2021: $732 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $695.41 | 2019-2022 | |
| Lilly USA, LLC | $296.99 | 2019-2021 | |
| Abbvie INC. | $194.51 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $154.46 | 2019-2020 | |
| Amgen INC. | $135.40 | 2019-2021 | |
| Glaxosmithkline, LLC. | $84.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.10 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.41 | 2020-2022 | |
| Pfizer INC. | $61.76 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $57.25 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.51 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $50.19 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $36.36 | 2019-2021 | |
| Amarin Pharma, INC. | $28.65 | 2019 | |
| Allergan, INC. | $25.63 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.41 | 2019-2020 | |
| Shire North American Group INC | $16.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.52 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.87 | 2021 | |
| Bausch Health US, LLC | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Asihene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.